GlassScriptPhysician profile
Carolyn L Weinstein
NPI 1962453811
$2,323.76
in general payments reported to CMS, 2019-2025
25 companies · $593 in 2025
The $593 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $308 · 2022: $525 · 2023: $471 · 2024: $426 · 2025: $593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,390 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,390.24 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $454.15 | 2022-2025 | Veozah |
| Exeltis, USA INC. | $301.76 | 2021-2025 | Slynd |
| Abbvie INC. | $215.03 | 2021-2024 | |
| Evofem Biosciences, INC. | $196.25 | 2021-2023 | Phexxi |
| Daiichi Sankyo INC. | $153.22 | 2021-2025 | Injectafer, Vanflyta |
| Sumitomo Pharma America, INC. | $151.29 | 2023-2025 | Myfembree, Gemtesa |
| Organon LLC | $105.37 | 2021-2024 | Nexplanon |
| Coopersurgical, INC. | $86.80 | 2021-2024 | Paragard T 380a, Paragard T 380a |
| Pfizer INC. | $81.96 | 2022-2023 | |
| Mayne Pharma Commercial LLC | $73.99 | 2022-2025 | |
| Hologic Sales and Service, LLC | $68.84 | 2022-2023 | Affirm Prone Biopsy System, Thinprep 2000 Processor, Aptima |
| Bayer Healthcare Pharmaceuticals INC. | $58.72 | 2021-2025 | |
| Therapeuticsmd, INC. | $51.19 | 2021-2022 | |
| Smith+Nephew, INC. | $50.21 | 2024 | Pico |
| Mylan Pharmaceuticals INC. | $48.59 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $39.95 | 2025 | Zurzuvae |
| Millicent US INC | $37.95 | 2024 | Intrarosa |
| Shield Therapeutics INC | $32.62 | 2024-2025 | |
| Agile Therapeutics, INC. | $27.25 | 2021-2022 | |
| Scynexis, INC. | $20.99 | 2022 | |
| Myovant Sciences INC. | $16.43 | 2022 | |
| Merck Sharp & Dohme LLC | $13.71 | 2021 | |
| Vivus LLC | $13.42 | 2023 | Qsymia |
| Novo Nordisk INC | $13.28 | 2023 | |
| Aspira Women'S Health INC | $10.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carolyn Weinstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.